MannKind Corporation (MNKD)

Market Cap	1.14B
Revenue (ttm)	297.60M
Net Income (ttm)	30.12M
Shares Out	303.93M
EPS (ttm)	0.10
PE Ratio	36.25
Forward PE	17.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,451,412
Open	3.780
Previous Close	3.770
Day's Range	3.680 - 3.780
52-Week Range	3.630 - 7.630
Beta	1.01
Analysts	Buy
Price Target	9.75 (+159.31%)
Earnings Date	Aug 6, 2025

About MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company’s product pipelin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 28, 2004
• Employees: 407
• Stock Exchange: NASDAQ
• Ticker Symbol: MNKD
• Website: https://www.mannkindcorp.com

Analyst Forecast

According to 4 analysts, the average rating for MNKD stock is "Buy." The 12-month stock price forecast is $9.75, which is an increase of 159.31% from the latest price.

Price Target

$9.75

(159.31% upside)

Analyst Consensus: Buy